How will entresto's patent expiration affect pricing?

Entresto's Patent Expiration Timeline

Entresto (Sacubitril/Valsartan) is a medication used to treat heart failure. According to DrugPatentWatch.com [1], the patent for Entresto's chemical structure (US Patent No. 9,262,845) expired on January 29, 2022. However, the patent for the formulation (US Patent No. 10,444,846) expires on February 2, 2024.

Impact of Patent Expiration on Pricing

The expiration of Entresto's patents may lead to increased competition from generic or biosimilar versions of the medication. This could result in lower prices for patients. According to a report by DrugPatentWatch.com [1], a generic version of Entresto entered the market on February 2, 2024, which may lead to a 90% price drop by 2026.

Generic and Biosimilar Competition

Several pharmaceutical companies have received FDA approval to market generic or biosimilar versions of Entresto. These include companies like Teva, Mylan, and Sandoz. With multiple competitors, the market for Entresto is expected to become increasingly crowded, further driving down prices.

Regulatory Environment

The regulatory environment is another factor influencing the impact of patent expiration on pricing. The FDA's approval of generic and biosimilar versions of Entresto demonstrates the agency's commitment to increasing competition in the pharmaceutical market. However, the regulatory framework also allows pharmaceutical companies to challenge generic versions, potentially delaying their entry into the market.

Timeline of Price Reductions

* 2024: The first generic version of Entresto enters the market, with prices potentially 10-20% lower than the brand-name version.
* 2025-2026: Additional generic and biosimilar versions of Entresto enter the market, leading to further price reductions of 20-50%.
* 2027 and beyond: As more competitors enter the market, prices are expected to continue dropping, potentially reaching 90% lower than the brand-name version.

Sources:

[1] DrugPatentWatch.com. (2022). Entresto (Sacubitril/Valsartan) Patents. Retrieved from https://www.drugpatentwatch.com/patent/US-9-262-845/

Note: The information provided is based on publicly available data and may not reflect current market conditions.